candesartan cilexetil + placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cluster Headache
Conditions
Cluster Headache
Trial Timeline
Mar 1, 2005 → Dec 1, 2009
NCT ID
NCT00184587About candesartan cilexetil + placebo
candesartan cilexetil + placebo is a phase 2 stage product being developed by AstraZeneca for Cluster Headache. The current trial status is completed. This product is registered under clinical trial identifier NCT00184587. Target conditions include Cluster Headache.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00120003 | Phase 3 | Completed |
| NCT00184587 | Phase 2 | Completed |
Competing Products
8 competing products in Cluster Headache
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Galcanezumab 300 mg + Placebo | Eli Lilly | Phase 3 | 77 |
| Galcanezumab | Eli Lilly | Phase 3 | 77 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| SOM230 + Placebo | Novartis | Phase 2 | 52 |
| Bosutinib + Imatinib | Pfizer | Phase 3 | 76 |
| Eptinezumab + Placebo | Lundbeck | Phase 3 | 74 |
| Eptinezumab | Lundbeck | Phase 3 | 74 |
| Methylprednisolone | Brain Biotech | Approved | 77 |